Last reviewed · How we verify
Finafloxacin i.v. solution 200 mg — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Finafloxacin i.v. solution 200 mg (Finafloxacin i.v. solution 200 mg) — MerLion Pharmaceuticals GmbH.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Finafloxacin i.v. solution 200 mg TARGET | Finafloxacin i.v. solution 200 mg | MerLion Pharmaceuticals GmbH | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Finafloxacin i.v. solution 200 mg CI watch — RSS
- Finafloxacin i.v. solution 200 mg CI watch — Atom
- Finafloxacin i.v. solution 200 mg CI watch — JSON
- Finafloxacin i.v. solution 200 mg alone — RSS
Cite this brief
Drug Landscape (2026). Finafloxacin i.v. solution 200 mg — Competitive Intelligence Brief. https://druglandscape.com/ci/finafloxacin-i-v-solution-200-mg. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab